Datapoint: Actemra Granted EUA for Use in COVID Patients

The FDA last week granted Roche’s Actemra an emergency use authorization to treat both adult and juvenile patients hospitalized with COVID-19. The arthritis drug was previously approved for compassionate use, but can now be administered to COVID patients who require oxygen support, in tandem with corticosteroids. For the treatment of rheumatoid arthritis, the intravenous form of Actemra holds covered or better status for 93% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/28/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 13

Datapoint: Three States to Launch New Exchange Marketplaces

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 12

Datapoint: Centene Takes on Major Medicare Expansion for 2022

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today